Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.59 |
| ▸ | LATS1 | O95835 | 5/20 | 0.50 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979110 | 0.80 | CYP1A2 (0.52) | GBA1LATS1LATS2ALDH1A1MAPT | |
| SCHEMBL18354065 | 0.75 | GBA1 (1.00) | GBA1ALDH1A1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL12039884 | 0.74 | LATS1 (0.61) | GBA1LATS1LATS2ALDH1A1 | |
| SCHEMBL18353944 | 0.70 | GBA1 (0.93) | GBA1ALDH1A1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL12039897 | 0.69 | CYP1A2 (0.55) | GBA1LATS1LATS2ALDH1A1MAPT | |
| SCHEMBL18354422 | 0.69 | GBA1 (0.87) | GBA1ALDH1A1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL20547821 | 0.68 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL1083881 | 0.68 | PDE5A (0.78) | GBA1ALDH1A1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL17532859 | 0.67 | L3MBTL1 (0.47) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18354333 | 0.67 | GBA1 (1.00) | GBA1ALDH1A1MAPTSMN1; SMN2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319409-A1 | 7-AZA-QUINAZOLINE PDE10 INHIBITORS | COX CHRISTOPHER D (US) | 2011-12-29 | — | — | US | claimed |
| US-20110319409-A1 | 7-AZA-QUINAZOLINE PDE10 INHIBITORS | COX CHRISTOPHER D (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319409-A1 | 7-AZA-QUINAZOLINE PDE10 INHIBITORS | COX CHRISTOPHER D (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319409-A1 | 7-AZA-QUINAZOLINE PDE10 INHIBITORS | COX CHRISTOPHER D (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319409-A1 | 7-AZA-QUINAZOLINE PDE10 INHIBITORS | PDE5A, PDE12, PDE7B | GBA1 355/4885LATS1 4435/4885LATS2 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.